Intrathoracic photodynamic therapy: A canine normal tissue tolerance study and early clinical experience

✍ Scribed by Zelig A. Tochner; Harvey I. Pass; Paul D. Smith; Thomas F. Delaney; Merle Sprague; Anne M. Deluca; Frank Harrington; Gunter F. Thomas; Richard Terrill; John D. Bacher; Angelo Russo

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 724 KB
• Volume: 14
• Category: Article
• ISSN: 0196-8092
• DOI: 10.1002/1096-9101(1994)14:2<118::aid-lsm1900140204>3.0.co;2-5

✦ Synopsis

Surgery with intraoperative photodynamic therapy (PDT) has the potential to improve the treatment of pleural malignancies. Before embarking on such treatment in humans, however, thoracic tissue tolerance to PDT was studied.

For each of three (1 week, 1 month, and 6 month) study endpoints, one control (no Photofrin I1 [PII]) and four treated animals underwent thoracotomy 72 hours after I.V. injection (6 mg/ kg) PII. Red light (630 nm) was delivered (5-10 J/cm2) to the pleural surface (1 cm diameter) of selected thoracic organs.

No clinical differences were observed between PDT and control dogs. The control showed no histological changes; however, in the treated animals focal areas of coagulation necrosis were found at 1 week which progressed to fibrosis at 1 month. The extent and depth of injury was proportional to light dose. The lung was the most sensitive; the chest wall was the most resistant. Myocardium had superficial damage, whereas coronary arteries appeared normal.

The results provide the basis for proceeding to phase I human trials in the evaluation of PDT as an intraoperative adjuvant treatment in the management of pleural malignancies. 0